Preclinical data shows EntreMed's 2ME2 compound reduces severity of joint inflammation in arthritis

By Lisa Kerner

Charlotte, N.C., June 22 - EntreMed, Inc. said preclinical data demonstrated that daily oral administration of its lead compound, 2-methoxyestradiol (2ME2) reduced severity of joint inflammation and inhibited articular joint damage in rheumatoid arthritis, as measured by high-resolution radiographs of bone erosions.

EntreMed collaborator Ernest Brahn of the University of California Los Angeles, School of Medicine presented the data at the Annual European Congress of Rheumatology EULAR 2006 in Amsterdam.

"These preclinical data further define the impact of 2ME2 on inflammation and disease progression and indicate that 2ME2 may represent a novel agent for the treatment of rheumatoid arthritis," Brahn said in a company news release.

"The demonstration that 2ME2 inhibits angiogenesis in this model of rheumatoid arthritis now establishes a mechanistic link that leads to the involution of collagen-induced arthritis."

A system disease affecting more than 2 million American adults, rheumatoid arthritis causes pain, stiffness, redness, swelling and loss of function in the joint.

Located in Rockville, Md., EntreMed is a clinical-stage pharmaceutical company that developing therapeutics for the treatment of cancer and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.